462 related articles for article (PubMed ID: 17846394)
21. [Differences in the relative incidence of adverse drug reactions in relation to age? An evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center)].
Ciorciaro C; Hartmann K; Kuhn M
Schweiz Med Wochenschr; 1998 Feb; 128(7):254-8. PubMed ID: 9540150
[TBL] [Abstract][Full Text] [Related]
22. Study dispels assumptions about adverse drug events.
Rollins G
Rep Med Guidel Outcomes Res; 2001 Aug; 12(17):1-2, 5. PubMed ID: 12296363
[No Abstract] [Full Text] [Related]
23. Emergency department visits for antibiotic-associated adverse events.
Shehab N; Patel PR; Srinivasan A; Budnitz DS
Clin Infect Dis; 2008 Sep; 47(6):735-43. PubMed ID: 18694344
[TBL] [Abstract][Full Text] [Related]
24. Reported adverse event cases of methemoglobinemia associated with benzocaine products.
Moore TJ; Walsh CS; Cohen MR
Arch Intern Med; 2004 Jun; 164(11):1192-6. PubMed ID: 15197044
[TBL] [Abstract][Full Text] [Related]
25. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
Souayah N; Nasar A; Suri MF; Qureshi AI
J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
[TBL] [Abstract][Full Text] [Related]
26. [Adverse drug events in out-patients as the cause of an initial consultation to neurology].
Ortin Castaño A; Otero MJ
Neurologia; 2006 Jun; 21(5):232-8. PubMed ID: 16788865
[TBL] [Abstract][Full Text] [Related]
27. Silicone gel breast implant adverse event reports to the Food and Drug Administration, 1984-1995.
Brown SL; Parmentier CM; Woo EK; Vishnuvajjala RL; Headrick ML
Public Health Rep; 1998; 113(6):535-43. PubMed ID: 9847926
[TBL] [Abstract][Full Text] [Related]
28. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden.
Jacobsson I; Jönsson AK; Gerdén B; Hägg S
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1039-47. PubMed ID: 19650152
[TBL] [Abstract][Full Text] [Related]
29. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
30. Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration.
Ehrenpreis ED; Parakkal D; Semer R; Du H
Colorectal Dis; 2011 Sep; 13(9):e270-5. PubMed ID: 21689347
[TBL] [Abstract][Full Text] [Related]
31. Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC; Smith MA; Gelin MN; Heathcote SC
Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
[TBL] [Abstract][Full Text] [Related]
32. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
[TBL] [Abstract][Full Text] [Related]
33. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
[TBL] [Abstract][Full Text] [Related]
34. Adverse events from cough and cold medications in children.
Schaefer MK; Shehab N; Cohen AL; Budnitz DS
Pediatrics; 2008 Apr; 121(4):783-7. PubMed ID: 18227192
[TBL] [Abstract][Full Text] [Related]
35. Are novel drugs more risky for patients than less novel drugs?
Olson MK
J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
[TBL] [Abstract][Full Text] [Related]
36. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
37. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children.
Mosholder AD; Gelperin K; Hammad TA; Phelan K; Johann-Liang R
Pediatrics; 2009 Feb; 123(2):611-6. PubMed ID: 19171629
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.
Gagne JJ; Maio V; Rabinowitz C
J Clin Pharm Ther; 2008 Apr; 33(2):141-51. PubMed ID: 18315779
[TBL] [Abstract][Full Text] [Related]
39. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
[TBL] [Abstract][Full Text] [Related]
40. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
Wysowski DK; Nourjah P; Swartz L
Arch Intern Med; 2007 Jul; 167(13):1414-9. PubMed ID: 17620536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
